Welcome to our dedicated page for Ionis Pharmaceuticals news (Ticker: IONS), a resource for investors and traders seeking the latest updates and insights on Ionis Pharmaceuticals stock.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) is a leading biotechnology company headquartered in Carlsbad, California. Founded in 1989, Ionis has been pioneering the discovery and development of antisense drugs, with an impressive portfolio of over 1300 patents. Ionis focuses on creating innovative RNA-targeted therapies for complex diseases, particularly in the areas of cardiovascular, metabolic, neurological, and rare genetic disorders.
Ionis has successfully brought several groundbreaking medicines to market. Notable achievements include the development of Spinraza, in collaboration with Biogen, which was launched in 2016 to treat spinal muscular atrophy, a rare neuromuscular disorder. In 2023, Biogen also launched Qalsody for ALS, further extending the impact of Ionis' antisense technology.
Through its cardiovascular-focused subsidiary, Akcea Therapeutics, Ionis has introduced drugs like Tegsedi for ATTR amyloidosis and Waylivra in Europe for cardiology indications. The company continues to advance its pipeline with promising candidates such as olezarsen, an investigational RNA-targeted therapy for familial chylomicronemia syndrome (FCS). Ionis' ongoing Phase 3 trials for olezarsen have shown promising results, with significant reductions in triglyceride levels and improvements in related health outcomes.
Ionis' commitment to innovation and patient care is also evident in its robust financial health and strategic partnerships. With a deep understanding of disease biology and cutting-edge technology, Ionis continues to drive advancements in RNA therapies and gene editing, aiming to deliver life-changing medicines for patients around the world.
Recently, Ionis announced positive clinical trial results for several of its investigational drugs and plans to pursue regulatory approvals for these therapies. The company's pipeline is well-positioned to address unmet medical needs in various therapeutic areas, promising a steady flow of new treatments in the coming years.
For more detailed information about Ionis Pharmaceuticals, its products, and career opportunities, visit their official website at www.ionispharma.com.
Biogen and Ionis Pharmaceuticals announced the Phase 1 study results of BIIB078, an investigational drug for C9orf72-associated ALS. The study, involving 106 participants, found that BIIB078 did not demonstrate any clinical benefit and failed to meet secondary efficacy endpoints. As a result, the clinical program for BIIB078 will be discontinued. Although well-tolerated, the study highlighted that the disease mechanism is more complex than initially hypothesized. Both companies remain committed to advancing ALS research and addressing this neurodegenerative disease.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced its participation in several upcoming investor conferences. Key events include:
- Stifel 2022 Virtual CNS Days on March 28, 2022
- Guggenheim Virtual Genomic Medicines and Rare Disease Day on April 1, 2022
- Needham 21st Annual Virtual Healthcare Conference on April 11, 2022
- Bank of America 2022 Healthcare Conference on May 11, 2022, in Las Vegas, NV
Ionis Pharmaceuticals has published positive Phase 2 results for donidalorsen, an investigational treatment for hereditary angioedema (HAE). The study showed a 90% reduction in angioedema attacks with 80 mg monthly doses compared to placebo, alongside significant improvement in quality of life. The treatment was well-tolerated with no serious adverse events noted. These findings support the ongoing Phase 3 study for donidalorsen, emphasizing Ionis' commitment to addressing unmet medical needs in HAE patients.
Ionis Pharmaceuticals (Nasdaq: IONS) announced it is accepting applications for the Janice Wiesman Young Investigator Grant Program, honoring Dr. Wiesman for her contributions to understanding transthyretin amyloidosis (ATTR). The program offers $50,000 annually for two years to U.S. researchers advancing ATTR knowledge, with applications due by April 4, 2022. The inaugural grants were awarded to Dr. Trejeeve Martyn and Dr. Jeremy Slivnick for their research on cardiac amyloidosis. March is also recognized as Amyloidosis Awareness Month, highlighting the disease's significance.
Ionis Pharmaceuticals (Nasdaq: IONS) will engage in a panel discussion focused on orphan neurological disease therapeutics at the upcoming Cowen 42nd Annual Health Care Conference. The event is scheduled for 9:10 a.m. ET on March 7, 2022. Interested parties can access a live webcast on the company's Investors & Media section of their website, with a replay available for a limited time. Ionis boasts over 30 years in RNA-targeted therapy, including three marketed medicines and a robust late-stage pipeline that emphasizes neurological and cardiometabolic franchises.
Ionis Pharmaceuticals reported strong financial results for 2021, exceeding guidance with total revenues of $810 million, driven by significant partner payments. The company has a solid cash position of $2.1 billion, enabling continued investment in R&D. Key achievements include collaborations with AstraZeneca on eplontersen and ongoing Phase 3 studies for multiple therapies. Positive Phase 2 results for olezarsen and donidalorsen were also announced. For 2022, Ionis expects revenue of over $575 million and a net loss of less than $275 million.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) will host a live webcast on February 24 at 11:30 a.m. ET to discuss its fourth quarter and full year 2021 financial results. The webcast will also cover the company's pipeline and business progress. Access the webcast and replay through the company's investor relations page. Ionis is a leader in RNA-targeted therapy, offering three marketed medicines and a robust late-stage pipeline focused on neurological and cardiometabolic diseases.
Pfizer and Ionis Pharmaceuticals announced the termination of the clinical development program for vupanorsen (PF-07285557), an investigational antisense therapy aimed at cardiovascular risk reduction and severe hypertriglyceridemia. Despite meeting its primary endpoint of reducing non-HDL cholesterol and triglycerides in a Phase 2b study, the results were insufficient to justify further development. Additionally, vupanorsen was linked to dose-dependent liver fat increases and elevated liver enzymes. Pfizer will return development rights to Ionis, which licensed vupanorsen in November 2019.
Ionis Pharmaceuticals has received orphan drug designation from the FDA for eplontersen, an investigational antisense therapy aimed at treating transthyretin-mediated amyloidosis. This designation provides Ionis with key incentives, including tax credits and seven years of market exclusivity after approval. Eplontersen, currently in Phase 3 trials, targets both hereditary and non-hereditary forms of the disease, which can lead to severe complications such as heart failure and nerve damage. The company's collaboration with AstraZeneca further supports the development of this promising treatment.
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has appointed Joseph T. Baroldi as executive vice president and chief business officer, effective January 31, 2022, and Eric P. Bastings, M.D., as vice president of development strategy. Baroldi, with over 20 years of experience, previously served as COO at Avidity Biosciences and held various roles at Ionis. Dr. Bastings brings over 20 years of regulatory experience from the FDA. The appointments aim to enhance business development and clinical leadership, crucial for advancing Ionis' innovative neurology pipeline.
FAQ
What is the current stock price of Ionis Pharmaceuticals (IONS)?
What is the market cap of Ionis Pharmaceuticals (IONS)?
What does Ionis Pharmaceuticals specialize in?
Where is Ionis Pharmaceuticals located?
What are some key products developed by Ionis Pharmaceuticals?
What is the latest development in Ionis' pipeline?
Who are some of Ionis' key partners?
How does Ionis Pharmaceuticals contribute to RNA therapy innovation?
What is olezarsen and what does it treat?
How can I learn more about career opportunities at Ionis Pharmaceuticals?
What recent clinical trials has Ionis Pharmaceuticals announced?
How does Ionis Pharmaceuticals support patients with rare diseases?
